MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) recall
FDA recall D-0553-2026 · initiated Apr 24, 2026
Wisconsin Pharmacal Company recalled MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) in Apr 2026 — an FDA Class I recall (D-0553-2026) because Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
Most serious — a reasonable probability that use will cause serious harm or death.
Why it was recalled
Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
Sterility could not be assured
The maker could not guarantee the product was sterile. That matters most for injections and eye products, where a contaminated dose reaches past the body's defences.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 690 tubes
Details
- Product
- MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g), Manufactured by: Pharmacal 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037.
- Recalling company
- Wisconsin Pharmacal Company
- Classification
- Class I
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- USA Nationwide and Bahamas
- Initiated
- Apr 24, 2026
- FDA report date
- May 27, 2026
Frequently asked
- Was MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) recalled?
- Wisconsin Pharmacal Company recalled MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) in Apr 2026 — an FDA Class I recall (D-0553-2026) because Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus. Most serious — a reasonable probability that use will cause serious harm or death.
- Why was MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) recalled?
- Per the FDA enforcement record, the reason for recall D-0553-2026 was: Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
- Is a recalled MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. Most serious — a reasonable probability that use will cause serious harm or death. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) are affected?
- Distributed: USA Nationwide and Bahamas. The recall covers these lots — Lot #: 1024088, Exp 11/30/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0553-2026.